• 8:30 - 18:00 M-T / 8.30 - 15.00 F

HC016 Acute Spine Injury


The HC016 platform is a treatment of acute spinal cord injury in the initial stage of the lesion, based on mesenchymal stem cells derived from adipose tissue (ASC), improved with Histocell's proprietary technology.
ferrer
hc016-spine

Innovation

HC016 cells modulate the inflammatory process by releasing specific enzymes and growth factors.

Additionally, cells show increased survival rates following implant due to an enhanced resistance against the cytotoxic environment in the injury site.

Development stage

Clinical Phase I/II ongoing:

Phase I completed with 6 patients.

Phase IIa starts Q2 2019.

Co-development agreement with Ferrer.

Histocell

Histocell, S.L.
Parque Tecnológico 801A, 2º
48160 Derio
Bizkaia - Spain

+34 94 656 7900
info@histocell.com
www.histocell.com

Our values

We develop new healthcare products and cell therapy drugs to improve people's quality of life.

Copyright © Histocell